Transmembrane protein 25 abrogates monomeric EGFR-driven STAT3 activation in triple-negative breast cancer

doi:10.1002/mco2.492

PDF

MedComm ›› 2024, Vol. 5 ›› Issue (4) : e492. DOI: 10.1002/mco2.492

HIGHLIGHTS

Transmembrane protein 25 abrogates monomeric EGFR-driven STAT3 activation in triple-negative breast cancer

Chakrabhavi Dhananjaya Mohan¹, Kanchugarakoppal S. Rangappa², Gautam Sethi³()

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Chakrabhavi Dhananjaya Mohan, Kanchugarakoppal S. Rangappa, Gautam Sethi. Transmembrane protein 25 abrogates monomeric EGFR-driven STAT3 activation in triple-negative breast cancer. MedComm, 2024, 5(4): e492 https://doi.org/10.1002/mco2.492

References

1	J Bi, Z Wu, X Zhang, et al. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. Nat Commun. 2023;14(1):2342.
2	B Segura-Collar, R Gargini, E Tovar-Ambel, et al. The EGFR-TMEM167A-p53 axis defines the aggressiveness of gliomas. Cancers. 2020;12(1):208.
3	P Doolan, M Clynes, S Kennedy, et al. TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer. Tumour Biol. 2009;30(4):200-209.
4	S Hra?ovec, N Hauptman, D Glava?, et al. TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer. Dis Markers. 2013;34(2):93-104.